XIAOMI-W
01810
POP MART
09992
BABA-W
09988
4
MEITUAN-W
03690
5
BYD COMPANY
01211
HK Stock MarketDetailed Quotes
08247 BIOSINO BIO-TEC
- 0.540
- 0.0000.00%
Market Closed Apr 30 16:08 CST
78.14MMarket Cap-1.70P/E (TTM)
0.000High0.000Low0Volume0.540Open0.540Pre Close0.00Turnover0.00%Turnover RatioLossP/E (Static)144.71MShares1.38052wk High0.43P/B34.71MFloat Cap0.26052wk Low--Dividend TTM64.29MShs Float6.696Historical High--Dividend LFY0.00%Amplitude0.019Historical Low--Avg Price2000Lot Size--Div YieldTTM--Div Yield LFY
BIOSINO BIO-TEC Key Stats
All
YOY
| (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -9.00%263.07M | -3.82%133.83M | -22.52%289.07M | -23.61%210.56M | -19.31%139.15M | -19.71%71.1M | 7.14%373.07M | 5.32%275.66M | -1.28%172.44M | 9.48%88.56M |
| Operating income | -9.00%263.07M | -3.82%133.83M | -22.52%289.07M | -23.61%210.56M | -19.31%139.15M | -19.71%71.1M | 7.14%373.07M | 5.32%275.66M | -1.28%172.44M | 9.48%88.56M |
| Cost of sales | 4.35%-154.67M | -3.90%-75.3M | 28.70%-161.71M | 32.02%-108.67M | 29.22%-72.47M | 27.31%-39.16M | -10.83%-226.79M | -13.82%-159.85M | -9.35%-102.38M | -18.17%-53.87M |
| Operating expenses | 4.35%-154.67M | -3.90%-75.3M | 28.70%-161.71M | 32.02%-108.67M | 29.22%-72.47M | 27.31%-39.16M | -10.83%-226.79M | -13.82%-159.85M | -9.35%-102.38M | -18.17%-53.87M |
| Gross profit | -14.89%108.4M | -12.22%58.53M | -12.93%127.37M | -12.02%101.89M | -4.82%66.68M | -7.91%31.94M | 1.87%146.28M | -4.52%115.81M | -13.55%70.06M | -1.74%34.69M |
| Selling expenses | 4.64%-56.21M | -2.99%-31.63M | -7.22%-58.95M | -12.01%-49.5M | -7.90%-30.71M | 1.94%-14.49M | -2.15%-54.98M | 11.10%-44.19M | 19.74%-28.46M | 8.55%-14.78M |
| Administrative expenses | 2.06%-50.39M | 13.64%-22.28M | -15.12%-51.45M | -17.58%-38.34M | -20.63%-25.8M | -24.73%-11.92M | -13.29%-44.69M | -4.56%-32.6M | -0.78%-21.38M | -3.17%-9.56M |
| Research and development expenses | 6.67%-33.42M | -5.75%-16.87M | -33.27%-35.81M | -37.58%-25.68M | -32.75%-15.95M | -72.53%-8.75M | -7.71%-26.87M | -4.40%-18.66M | 3.89%-12.02M | 12.52%-5.07M |
| Impairment and provision | -1,396.70%-19.5M | ---- | -571.65%-1.3M | ---- | ---- | ---- | -50.39%-194K | ---- | ---- | ---- |
| -Other impairment is provision | -1,396.70%-19.5M | ---- | -571.65%-1.3M | ---- | ---- | ---- | -50.39%-194K | ---- | ---- | ---- |
| Special items of operating profit | 132.77%1.12M | 0.68%294K | -358.39%-3.42M | -110.13%-128K | -69.49%292K | -42.98%65K | 92.43%-745K | 198.83%1.26M | 16,050.00%957K | 500.00%114K |
| Operating profit | -112.24%-50.01M | -117.69%-11.95M | -225.33%-23.56M | -154.32%-11.75M | -160.01%-5.49M | -158.54%-3.16M | 288.89%18.8M | 1.73%21.62M | -22.75%9.15M | 31.54%5.39M |
| Financing cost | -45.34%-9.3M | -41.84%-4.19M | 6.15%-6.4M | 5.01%-4.8M | 7.92%-2.95M | -11.40%-1.44M | ---6.82M | 31.89%-5.05M | 41.73%-3.21M | 29.97%-1.29M |
| Share of profits of associates | -102.55%-317K | -99.81%5K | 88.59%12.41M | 151.31%8.47M | 113.21%2.66M | 38.87%-541K | 466.27%6.58M | 2,692.31%3.37M | 427.00%1.25M | -13.17%-885K |
| Share of profit from joint venture company | -57.14%-99K | 68.97%-9K | -36.96%-63K | -50.00%-42K | -61.11%-29K | -88.89%-17K | -111.19%-46K | 17.65%-28K | 37.93%-18K | ---9K |
| Earning before tax | -239.07%-59.72M | -177.88%-16.15M | -195.12%-17.61M | -140.76%-8.12M | -181.01%-5.81M | -260.55%-5.15M | 189.00%18.52M | 45.63%19.91M | 9.56%7.17M | 117.41%3.21M |
| Tax | 273.89%2.83M | 1.45%-2.17M | 62.26%-1.63M | -1.85%-2.58M | 9.80%-2.2M | 7.24%-1.01M | -32.86%-4.31M | -37.47%-2.54M | -76.94%-2.44M | -1.87%-1.09M |
| After-tax profit from continuing operations | -195.67%-56.89M | -128.61%-18.31M | -235.48%-19.24M | -161.56%-10.7M | -269.29%-8.01M | -391.03%-6.16M | 349.43%14.2M | 46.90%17.38M | -8.42%4.73M | 422.96%2.12M |
| Earning after tax | -195.67%-56.89M | -128.61%-18.31M | -235.48%-19.24M | -161.56%-10.7M | -269.29%-8.01M | -391.03%-6.16M | 349.43%14.2M | 46.90%17.38M | -8.42%4.73M | 422.96%2.12M |
| Minority profit | -89.08%-14.36M | -98.30%-5.13M | -224.56%-7.59M | -177.03%-4.71M | -162.30%-2.59M | -138.05%-1.03M | 41.77%6.1M | 52.78%6.11M | 24.71%4.15M | 156.58%2.71M |
| Profit attributable to shareholders | -265.14%-42.53M | -143.08%-13.18M | -243.70%-11.65M | -153.18%-5.99M | -1,038.24%-5.42M | -763.97%-5.13M | 811.05%8.11M | 43.90%11.27M | -68.52%578K | 8.90%-594K |
| Basic earnings per share | -267.50%-0.294 | -145.95%-0.091 | -242.86%-0.08 | -152.56%-0.041 | -1,025.00%-0.037 | -300.00%-0.04 | 800.00%0.056 | 56.00%0.078 | -69.23%0.004 | 0.00%-0.01 |
| Diluted earnings per share | -267.50%-0.294 | -145.95%-0.091 | -242.86%-0.08 | -152.56%-0.041 | -1,025.00%-0.037 | -300.00%-0.04 | 800.00%0.056 | 56.00%0.078 | -69.23%0.004 | 0.00%-0.01 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- |
| Auditor | -- | -- | Ernst & Young Huaming (Special General Partnership), Ernst & Young | -- | -- | -- | Ernst & Young Huaming (Special General Partnership), Ernst & Young | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.